VXRT Logo

Vaxart, Inc. (VXRT) 

NASDAQ
Market Cap
$137.94M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
304 of 775
Rank in Industry
178 of 433

Largest Insider Buys in Sector

VXRT Stock Price History Chart

VXRT Stock Performance

About Vaxart, Inc.

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, …

Insider Activity of Vaxart, Inc.

Over the last 12 months, insiders at Vaxart, Inc. have bought $13,578 and sold $0 worth of Vaxart, Inc. stock.

On average, over the past 5 years, insiders at Vaxart, Inc. have bought $14,939 and sold $108.51M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Watson W. Mark (director) — $13,578.

The last purchase of 20,000 shares for transaction amount of $13,578 was made by Watson W. Mark (director) on 2024‑06‑18.

List of Insider Buy and Sell Transactions, Vaxart, Inc.

2024-06-18Purchasedirector
20,000
0.01%
$0.68$13,578+14.99%
2022-12-28Purchasedirector
20,000
0.0152%
$0.76$15,140-1.30%
2022-06-22PurchaseInterim CFO
5,000
0.0037%
$3.22$16,100-64.14%
2022-01-10Saledirector
1,500
0.0012%
$6.01$9,015-42.60%
2021-11-30SaleSVP, Principal Accntng Officer
3,602
0.003%
$8.00$28,816-52.20%
2021-09-10SaleSVP, Principal Accntng Officer
1,801
0.0015%
$9.10$16,389-45.32%
2021-08-10SaleSVP, Chief Scientific Officer
10,000
0.0089%
$10.20$102,000-45.30%
2021-08-10SaleSVP, Principal Accntng Officer
1,801
0.0016%
$10.00$18,010-45.30%
2021-07-19SaleSVP, Principal Accntng Officer
1,800
0.0015%
$8.00$14,400-29.40%
2021-06-11Saledirector
10,000
0.0081%
$8.61$86,109-24.14%
2021-06-11SaleSVP, Principal Accntng Officer
1,802
0.0014%
$8.00$14,416-24.14%
2021-06-09SaleSVP, Principal Accntng Officer
47,555
0.0412%
$8.00$380,440-12.70%
2021-05-07Saledirector
100,000
0.0819%
$7.13$712,750-6.18%
2021-05-06Saledirector
100,000
0.078%
$6.54$653,890-2.45%
2021-03-04Saledirector
150,000
0.1327%
$6.04$906,450+16.22%
2020-11-23Saledirector
333,334
0.2702%
$6.32$2.11M+1.05%
2020-06-29Saledirector
9.39M
13.9107%
$8.29$77.8M-6.34%
2020-06-26Saledirector
18.23M
31.5118%
$10.38$189.19M-12.81%
2020-06-03Saledirector
400,000
0.5415%
$2.77$1.11M+150.91%
2020-06-02Saledirector
800,000
1.0089%
$2.75$2.2M+135.10%

Insider Historical Profitability

123.58%
Watson W. Markdirector
78125
0.0343%
$0.6120<0.0001%
Third Point LLCother
6890000
3.0288%
$0.6141<0.0001%
Finney Michael J.director
452572
0.199%
$0.6130<0.0001%
FAHIM RAAFAT E FPresident, CEO and CFO
373474
0.1642%
$0.6133+50%
ARMISTICE CAPITAL, LLCdirector
145523
0.064%
$0.61924+502.07%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$20M8.715.38MNew+$20M0.02
The Vanguard Group$10.98M4.788.45M+19.93%+$1.83M<0.0001
Geode Capital Management$2.85M1.242.19M+11.87%+$302,820.11<0.0001
Millennium Management LLC$2.46M1.071.89M+956.23%+$2.22M<0.01
BlackRock$2.31M11.77M-0.84%-$19,653.40<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.